News
BHST
1.505
-7.67%
-0.125
BioHarvest Sciences Earnings Call Signals Cautious Reset
TipRanks · 4h ago
BioHarvest Sciences Inc. Reports September 30, 2026 Financial Results
NASDAQ · 2d ago
Conference call: BioHarvest Sciences Lowers FY2026 Sales Guidance from $37.000M-$40.000M to $32.000M-$33.500M vs $37.461M Est
Benzinga · 2d ago
BioHarvest Sciences Q3 2026 Earnings Call Transcript
Benzinga · 2d ago
BioHarvest Sciences Inc. - Common Stock Q3 EPS $(0.15) Misses $(0.14) Estimate, Sales $7.867M Miss $9.371M Estimate
Benzinga · 2d ago
BioHarvest Sciences GAAP EPS of -$0.15 misses by $0.01, revenue of $7.9M misses by $1.41M
Seeking Alpha · 2d ago
BioHarvest Sciences Inc. (BHST) Reports Q3 Loss, Misses Revenue Estimates
NASDAQ · 2d ago
MiNK Therapeutics, Inc. (INKT) Reports Q3 Loss, Beats Revenue Estimates
NASDAQ · 3d ago
ImmunityBio (IBRX) Reports Q3 Loss, Misses Revenue Estimates
NASDAQ · 5d ago
Weekly Report: what happened at BHST last week (1102-1106)?
Weekly Report · 5d ago
Weekly Report: what happened at BHST last week (1026-1030)?
Weekly Report · 11/02 10:10
BioHarvest to Unveil Q3 2026 Results as It Deepens CDMO-Focused Strategy
TipRanks · 10/29 13:12
BioHarvest Sciences to Report Third Quarter 2026 Financial Results on November 12, 2026
Newsfile · 10/29 12:00
Wave Life Sciences (WVE) Reports Q3 Loss, Tops Revenue Estimates
NASDAQ · 10/27 11:40
Weekly Report: what happened at BHST last week (1019-1023)?
Weekly Report · 10/26 10:10
Weekly Report: what happened at BHST last week (1012-1016)?
Weekly Report · 10/19 10:10
BioHarvest Pushes Olive Cell Ingredient to Commercial Readiness, Expanding CDMO Pipeline
TipRanks · 10/13 12:11
BioHarvest Sciences' Proprietary Olive Cell Composition Attains Commercial Readiness, Now Available For Licensing And Commercialization
Benzinga · 10/13 11:23
BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity
Newsfile · 10/13 11:00
Weekly Report: what happened at BHST last week (1005-1009)?
Weekly Report · 10/12 10:15
More
Webull provides a variety of real-time BHST stock news. You can receive the latest news about Bioharvest through multiple platforms. This information may help you make smarter investment decisions.
About BHST
BioHarvest Sciences Inc. is a Canada-based botanical synthesis company. The Company leverages its technology platform to grow plant-based compounds, without the need to grow the underlying plant. It is leveraging its botanical synthesis technology to develop science-based therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking plant-based compounds, and as a creator of nutraceutical health and wellness products, which include dietary supplements. It delivers phytochemicals such as age-defying antioxidants and polyphenols used for wellness. Its product pipeline is focused on polyphenols, which include grape cells, olive cells, and pomegranate cells. Its process involves selecting the specific plant cells that can create the targeted ingredients. It offers VINIA, which is a nutraceutical containing the entire matrix of polyphenols contained in red grapes, including Piceid resveratrol.